CPCarlo Andrea Pivato

Carlo Andrea Pivato

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Carlo Andrea Pivato has a total of 273 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Complete versus incomplete coronary revascularisation in patients undergoing PCI after TAVI

    by Carlo Andrea Pivato, Nicole Fontana, Leon Gramss, Emanuele Di Angelantonio, Francesca Ieva, Cosmo Godino, Masaaki Nakase, Karsten Hug, Tobias Andreas Rheude, Antonio Jesús Muñoz-García, et al.

    Background: The optimal revascularisation strategy for patients undergoing percutaneous coronary intervention (PCI) after transcatheter aortic valve implantation (TAVI) remains undefined. In particular, the prognostic impact of complete revascularisation (CR) versus incomplete revascularisation (ICR) in this setting is unknown. Aims: To evaluate the long-term clinical outcomes of CR versus ICR in patients undergoing PCI after TAVI. Methods: We analysed 447 patients from the multicentre, international Revascularization After Transcatheter Aortic Valve Implantation (REVIVAL) registry who underwent PCI after TAVI between 2008 and 2023. Patients were classified as CR or ICR according to the presence of residual significant stenosis following PCI. The primary endpoint was the 4-year incidence of major adverse cardiovascular events (MACE), a composite of cardiovascular death, myocardial infarction or stroke. The Kaplan-Meier method was used to estimate cumulative event rates, and a weighted Cox regression model employing an entropy balance approach was used to adjust for possible confounders. Results: ICR was achieved in 132 patients (29.5%) and CR in 315 patients (70.5%). The mean follow-up after PCI was 1065±904 days (1213±938 in the ICR group; 1002±883 in the CR group). The crude 4-year incidence of MACE was 35.0% with ICR and 34.7% with CR (HR 0.93, 95% CI 0.62 to 1.39, p=0.710). Adjusted analysis confirmed no significant difference (32.5% vs 34.1%; HR 1.01, 95% CI 0.62 to 1.64, p=0.971). Conclusion: In this registry, CR after TAVI was common but not associated with improved outcomes compared with ICR. These results support a selective rather than systematic pursuit of CR in elderly, high-risk post-TAVI patients.

  • Aspirin for Stroke Primary Prevention: A Step Toward Genetic-Driven Personalized Medicine

    by Umberto Pensato, Guillaume Paré, Carlo Andrea Pivato

  • Open Access

    Hundreds of cardiac MRI traits derived using 3D diffusion autoencoders share a common genetic architecture

    by Sara Ometto, Soumick Chatterjee, Andrea Mario Vergani, Arianna Landini, Sodbo Sharapov, Edoardo Giacopuzzi, Alessia Visconti, Emanuele Bianchi, Federica Santonastaso, Emanuel M. Soda, et al.

    Biobank-scale imaging provides an unprecedented opportunity to characterise how thousands of organ phenotypes vary in populations. However, deriving specific phenotypes from imaging data requires time-consuming expert annotation, limiting scalability. In this study, we develop a 3D diffusion autoencoder to derive latent phenotypes from temporally resolved cardiac MRI data of 71,017 UK Biobank participants. These phenotypes are reproducible, heritable (h2 = [4—18%]), and significantly associated with cardiometabolic traits. To establish the genetic basis of such traits, we perform a genome-wide association study, identifying 89 significant common variants (P < 2.3 × 10−9) across 42 loci, including seven novel loci. Extensive multi-trait colocalisation analyses (PP.H4 > 0.8) link variants across phenotypic scales, from intermediate cardiac traits to cardiac disease endpoints. In conclusion, this study showcases the use of diffusion autoencoding methods as powerful tools for unsupervised phenotyping, genetic discovery and disease risk prediction using cardiac MRI data.

  • Open Access

    One-month dual antiplatelet therapy after biodegradable-polymer everolimus-eluting stent implantation in diabetic patients at high bleeding risk

    by Leon Gramss, Carlo Andrea Pivato, Andrea Pacchioni, Raffaele Piccolo, Carmine Musto, Gennaro Sardella, Ciro Indolfi, Bernhard Reimers, Gianluigi Condorelli, Luca Testa, et al.

    The duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) should be individualized according to each patient’s ischaemic and bleeding risks. In patients at high bleeding risk (HBR), abbreviated antiplatelet therapy reduces bleeding without an apparent increase in ischaemic events in largely unselected HBR populations undergoing PCI with biodegradable polymer sirolimus-eluting stents (BP-SES).1,2 Current guidelines do not recommend different post-PCI antithrombotic strategies solely on the basis of diabetes mellitus.3 However, diabetes is consistently associated with higher atherothrombotic burden and ischaemic risk, and whether the net clinical benefit of abbreviated DAPT is preserved among HBR patients with diabetes remains debated.4 Therefore, we evaluated whether diabetes modifies clinical outcomes among HBR patients treated with a 1-month DAPT regimen after implantation of a bioresorbable polymer everolimus-eluting stent (BP-EES) in the POEM trial (Performance of Bioresorbable Polymer-Coated Everolimus-Eluting Synergy Stent in Patients at HBR Undergoing Percutaneous Coronary Revascularization Followed by 1-Month DAPT).


  • Open Access

    Ultrasound evaluation of placental volume and placental vascular indices in women developing hypertensive disorders in pregnancy compared to controls: a systematic review and meta-analysis

    by Enrica Zambella, Annalisa Inversetti, Carlo A Pivato, Martina Cristodoro, Giulio G Stefanini, Nicoletta Di Simone

    Aims: To assess whether first-trimester placental volume (PV) and vascular indices differ between pregnancies that subsequently develop preeclampsia (PE) or gestational hypertension (GH) and normotensive controls. Methods and results: Following PRISMA guidelines, a systematic review and meta-analysis were carried out across PubMed, Embase, and Web of Science, from inception until March 2025. Cross-sectional, cohort, and case-control studies assessing first-trimester PV or vascular indices in pregnancies developing PE or GH vs. normotensive controls were included. Study outcomes were presented using mean difference (MD) with 95% confidence intervals (CIs) and heterogeneity among studies was assessed using I² statistics. Thirty-eight studies were included in the systematic review, and ultrasound was performed between 11 and 14 weeks of gestation in 36 studies. Significantly lower levels of PV were found in patients who developed PE (MD: −12.61, 95%CI: −19.05 to −6.17, P-value: 0.0001), and, interestingly, in patients who developed both early onset and late onset PE (MD: −20.61, 95%CI: −27.56 to −13.66, P-value < 0.00001, and MD: −11.89, CI95%: −17.00 to −6.78, P-value < 0.00001, respectively). Finally, significant lower levels of vascular indices were found in patients with PE (MD vascularization index: −4.69, 95%CI: −6.40 to −2.98, P-value <0.00001; MD flow index: −4.83, 95%CI: −6.59 to −3.07, P value < 0.00001; MD vascularization flow index: −1.98, 95%CI: −2.59 to −1.37, P-value <0.00001). Conclusion: First-trimester placental volume and vascular indices are lower in pregnancies that subsequently develop PE, but not GH. These findings suggest potential clinical utility, pending prospective validation and standardized measurement.


  • Open Access

    Clinical outcomes of percutaneous coronary interventions after transcatheter aortic valve replacement

    by Carlo A Pivato, Ottavia Cozzi, Nicole Fontana, Francesca Ieva, Gianluigi Condorelli, Cosmo Godino, Bernhard Reimers, Masaaki Nakase, Karsten Hug, Tobias Rheude, et al.

    Aims: The number of patients undergoing percutaneous coronary interventions (PCI) after transcatheter aortic valve replacement (TAVR) is expected to increase, but their prognosis remains poorly understood. Methods and results: Consecutive PCI patients with prior TAVR were compared to patients without prior TAVR between 2008 and 2023. The Kaplan–Meier method was used to estimate the 1-year incidence of major adverse cardiovascular events (MACE), defined as a composite of cardiovascular death or myocardial infarction. An entropy balance approach was implemented to adjust for imbalances in patient and procedural characteristics. Adjusted hazard ratios (HRs) were estimated using weighted Cox regression models. Comparing 420 PCI patients with prior TAVR (mean age 80.8 years, 37.1% women) to 1197 without (mean age 70.4 years, 24.6% women), 1-year MACE was higher in the prior TAVR group (8.7 vs. 3.7%; unadjusted HR 2.35, 95% CI 1.49–3.69; P < 0.001). After adjustment for clinical and procedural characteristics, prior TAVR remained associated with an increased risk of MACE (adjusted HR 2.36, 95% CI 1.08–5.16; P = 0.032). This was primarily driven by higher cardiovascular death (adjusted HR 3.12, 95% CI 1.10–8.79, P = 0.032), while the association with myocardial infarction was attenuated post-adjustment and no longer statistically significant. Conclusion: Patients undergoing PCI after TAVR experience a higher incidence of MACE compared to those undergoing PCI without prior TAVR, underscoring the importance of accurate patient selection before performing PCI in patients with chronic coronary syndrome and history of TAVR.


  • Cardiovascular safety of assisted reproductive technology: a meta-analysis

    by Carlo Andrea Pivato, Annalisa Inversetti, Gianluigi Condorelli, Alaide Chieffo, Paolo Emanuele Levi-Setti, Alessia Chiara Latini, Andrea Busnelli, Martina Messa, Martina Cristodoro, Renato Maria Bragato, et al.

    Background and Aims: The increasing use of assisted reproductive technology (ART) has raised concerns regarding its long-term cardiovascular safety due to potential hormonal imbalances and pro-thrombotic states. This study aimed to assess the long-term cardiovascular risk associated with fertility treatments in women. Methods: Following PRISMA guidelines, a systematic review and meta-analysis was conducted in MEDLINE (via PubMed) from inception to January 2024. Randomized, cohort, or case-control studies were included if fulfilling the following criteria: the association between ART and the subsequent cardiovascular outcome was reported and adjusted for confounding factors (at least age); the presence of a control group; and minimum 1-year follow-up. Effect size (ES) estimates of the association between fertility therapy and subsequent cardiovascular disease were pooled using the DerSimonian and Laird random-effects model. Heterogeneity was assessed with the I2 index. This study is registered on PROSPERO (CRD42024505605). Results: Of the 7298 articles screened, 10 studies were included, encompassing 500 664 women undergoing ART and 36 395 240 controls. The analysis found no significant increase in the long-term risk of major adverse cardiovascular events [ES 1.04, 95% confidence interval (CI) 0.88–1.23, I2 87.61%, P = .63], coronary heart disease (ES 0.88, 95% CI 0.71–1.10, I2 24.36%, P = .26), stroke (ES 1.21, 95% CI 0.92–1.59, I2 70.40%, P = .17), venous thromboembolism (ES 0.95, 95% CI 0.70–1.28, I2 49.13%, P = .73), hypertension (ES 1.08, 95% CI 0.88–1.32, I2 94.63%, P = .46), or diabetes (ES 1.03, 95% CI 0.86–1.22, I2 78.44%, P = .77). Assisted reproductive technology was associated with a lower risk of heart failure (ES 0.75, 95% CI 0.60–0.94, I2 0.00%, P = .01). Conclusions: Assisted reproductive technology use does not appear to be significantly associated with an increased long-term risk of cardiovascular diseases in women. While these findings suggest the cardiovascular safety of fertility treatments, further research is warranted.


  • Open Access

    One‐month DAPT after biodegradable‐polymer everolimus‐eluting stent implantation in women at high‐bleeding risk: Insights from the POEM trial

    by Matteo Maurina, Carlo Andrea Pivato, Vijay Kunadian, Luca Testa, Carlo Briguori, Andrea Pacchioni, Alessia Chiara Latini, Nicola Cesani, Raffale Piccolo, Carmine Musto, et al.

    Aims: We conducted a prespecified subanalysis of the POEM trial to assess the association between sex and clinical outcomes following a short 1‐month dual‐antiplatelet‐therapy (DAPT) period after percutaneous coronary intervention (PCI) with bioresorbable polymer everolimus‐eluting stent (BP‐EES) among patients at high bleeding risk (HBR). Background: Shortening the DAPT period after PCI is an effective bleeding avoidance strategy with contemporary drug‐eluting stents. Whether sex affects the risk of adverse events following PCI is still debated. Methods: Patients at HBR undergoing PCI with BP‐EES were enrolled and treated with 1‐month DAPT. If anticoagulation was needed, study participants received an oral anticoagulant (OAC) in addition to a P2Y 12 inhibitor for 1 month, followed by OAC only thereafter. The primary endpoint was a composite of cardiac death, myocardial infarction, or definite/probable stent thrombosis at 12 months. We report sex‐based outcomes of patients included in the POEM study. Results: We enrolled 129 (29.1%) women and 314 (70.9%) men. Women were older, with lower hemoglobin levels, and worse renal function. Accordingly, they had a trend for a greater number of HBR criteria fulfilled and a higher PARIS bleeding score. However, they were not at a significantly higher risk for the primary endpoint (men vs. women: 5.17% vs. 3.94%; HR 1.30; 95% CI: 0.48‐3.54, p = 0.61), or any of the hemorrhagic and ischemic secondary endpoints. Conclusions: This prespecified subanalysis of the POEM trial suggests that 1‐month DAPT following PCI with BP‐EES may be a safe and effective therapeutic strategy for women at HBR.

  • Open Access

    One-month DAPT after biodegradable-polymer everolimus-eluting stent implantation in patients at high-bleeding risk: an individual patient data pooled analysis of the SENIOR and POEM trials

    by Carlo A Pivato, Giulio Stefanini, Daniele Giacoppo, Georgios Sideris, Luca Testa, Dragica Paunovic, Carlo Briguori, Ciro Indolfi, Bernhard Reimers, Peter Sinnaeve, et al.

    Aims: Dual antiplatelet therapy (DAPT) can be shortened up to 1 month in high-bleeding risk (HBR) patients receiving a contemporary biodegradable-polymer sirolimus-eluting stent. We aimed to summarize the evidence on a similar DAPT regimen after biodegradable-polymer everolimus-eluting stent (EES) implantation in patients at HBR. Methods and results: We pooled the individual participant data from the available trials evaluating this strategy, namely, the SENIOR and the POEM trials. Inclusion criteria were ≥1 biodegradable-polymer EES implantation and ≤1-month duration of DAPT. The primary endpoint was the 1-year composite of cardiovascular death, myocardial infarction, or stroke. Major bleeding was defined as Bleeding Academic Research Consortium (BARC) type 3–5 bleeding. Landmark analyses were performed at 1 month, the time point for intended DAPT interruption. We included 766 participants (age 77.5 ± 8.2 years, women 31.9%), 323 from the SENIOR and 443 from the POEM trial. The primary endpoint occurred in 45 participants (6.0%; 95% confidence interval [CI], 4.3–7.7%) through 1 year of follow-up, with 21 (2.8%; 95% CI, 1.6–3.9%) events during the first month and 24 (3.4%; 95% CI, 2.0–4.7%) thereafter. The incidences of cardiovascular death, myocardial infarction, and stroke were 2.2% (95% CI, 0.36–2.50%), 3.1% (95% CI, 1.8–4.3%), and 1.2% (95% CI, 0.4–2.0%), respectively. BARC type 3–5 bleeding ocuurred in 1.1% (95% CI, 0.3–1.8%) at 1 month and 2.9% (95% CI, 1.6–4.1%) at 1 year. Conclusion: HBR patients receiving biodegradable-polymer EES had few ischemic and bleeding events when given 1 month of DAPT. One-month DAPT after biodegradable-polymer EES implantation seems safe in patients at HBR.